AMRI awarded seven-year NIH contract

By Melissa Fassbender contact

- Last updated on GMT

(Image: BernardaSv)
(Image: BernardaSv)
AMRI will support the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies under a seven-year contract with the NIH.

The National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), awarded the contract for which the bulk of the work will be carried out at AMRI’s Albany, NY facilities.

The contract research, development and manufacturing organization (CDMO) provides services for various other NIH-funded programs, most recently for the Blueprint Neurotherapeutics Network​ (BPN).

AMRI also is a Dedicated Chemical Biology Consortium (CBC) Center for the NCI Experimental Therapeutics (NExT) Program, the National Center for Advancing Translational Sciences (NCATS).

Christopher Conway, senior vice president of discovery, development and analytical services and fine chemicals, at AMRI, commented in a press release:

“Our new contract with the NIH not only enhances AMRI’s ability to positively impact the health of the general public, but it also serves as a testament of our work, giving prospective customers confidence in our aptitude to solve complex scientific challenges.”

In response to a growing customer base, the company recently expanded​ its container closure integrity testing (CCIT) services in the European Union (EU), with further services to be added later in the year.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars